COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,971 Articles (22,604 medRxiv, 8,367 bioRxiv)

Most recent first Previous |  Page 700: Articles 6991-7000  | Next

A Bivalent Omicron-containing Booster Vaccine Against Covid-19
Chalkias, S., Harper, C., Vrbicky, K., Walsh, S. R., Essink, B., Brosz, A., McGhee, N., Tomassini, J. E., Chen, X., Chang, Y., Sutherland, A., Montefiori, D. C., Girard, B., Edwards, D. K., Feng, J., Zhou, H., Baden, L. R., Miller, J. M., Das, R.
10.1101/2022.06.24.22276703 — Posted: 2022-06-25
SARS-CoV-2 evolution and evasion from multiple antibody treatments in a cancer patient
Shapira, G., Weiner, C., Sorek Abramovich, R., Gutwein, O., Rainy, N., Benveniste-Levkovitz, P., Gordon, E., Bar Chaim, A., Shomron, N.
10.1101/2022.06.25.22276445 — Posted: 2022-06-25
Predicting the antigenic evolution of SARS-COV-2 with deep learning
Han, W., Chen, N., Wang, Y., Sun, S., Gao, X.
10.1101/2022.06.23.497375 — Posted: 2022-06-24
A cell-based, spike protein binding assay highlights differences in antibody neutralising capacity for SARS-CoV-2 variants
Harrison, N., Richardson, L., Pallini, C., Morano, I., Jinks, E., Cowley, J., Chan, H., Hill, H., Matas de las Heras, C., Teodosio, A., Lavado, A. S., Dafforn, T. R., Grammatopoulos, D. K., Gordon, J., Brady, C. A., Young, L. S., Barnes, N. M., Stamataki, Z., Qureshi, O. S.
10.1101/2022.06.24.496409 — Posted: 2022-06-24
In Vitro Evaluation and Mitigation of Niclosamide Liabilities as a COVID-19 Treatment.
Wotring, J. W., McCarty, S. M., Shafiq, K., Zhang, C. J., Nguyen, T., Meyer, S. R., Fursmidt, R., Mirabelli, C., Clasby, M. C., Wobus, C. E., O'Meara, M. J., Sexton, J. Z.
10.1101/2022.06.24.497526 — Posted: 2022-06-24
DESIGN OF A CHIMERIC ACE-2/Fc-SILENT FUSION PROTEIN WITH ULTRAHIGH AFFINITY AND NEUTRALIZING CAPACITY FOR SARS-CoV-2 VARIANTS
Uhal, B., Bodie, N. M., Connolly, D., Chu, J.
10.1101/2022.06.23.497326 — Posted: 2022-06-24
Investigating the mutations in the SARS-CoV-2 proteins among European countries
Abavisani, M., Rahimian, K., Khayami, R., Kodori, M., Sisakht, M. M., Mahmanzar, M., Meshkat, Z.
10.1101/2022.06.23.497239 — Posted: 2022-06-24
The Functional Landscape of SARS-CoV-2 3CL Protease
Iketani, S., Hong, S. J., Sheng, J., Bahari, F., Culbertson, B., Atanaki, F. F., Aditham, A. K., Kratz, A. F., Luck, M. I., Tian, R., Goff, S. P., Montazeri, H., Sabo, Y., Ho, D. D., Chavez, A.
10.1101/2022.06.23.497404 — Posted: 2022-06-24
Monitoring SARS-CoV-2 infection using a double reporter-expressing virus
Chiem, K., Park, J.-G., Morales Vasquez, D., Plemper, R. K., Torrelles, J. B., Kobie, J., Walter, M. R., Ye, C., Martinez-Sobrido, L.
10.1101/2022.06.23.497376 — Posted: 2022-06-24
Association of physical activity and the risk of COVID-19 hospitalization: a dose-response meta-analysis
Li, D., Jin, S., Lu, S.
10.1101/2022.06.22.22276789 — Posted: 2022-06-23

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).